The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions

M. B. Hilscher, L. J. Odell, L. J. Myhre, L. Prokop, J. Talwalkar

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.

Original languageEnglish (US)
Pages (from-to)587-591
Number of pages5
JournalJournal of Clinical Pharmacy and Therapeutics
Volume41
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Fibrosis
Drug Therapy
Drug-Related Side Effects and Adverse Reactions
Uncertainty
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Pharmaceutical Preparations
Population
Fear
Prescriptions
Patient Care
Anti-Inflammatory Agents
Retrospective Studies
Guidelines
Liver
Incidence

Keywords

  • drug interaction
  • liver
  • pharmacists

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The pharmacotherapy of cirrhosis : concerns and proposed investigations and solutions. / Hilscher, M. B.; Odell, L. J.; Myhre, L. J.; Prokop, L.; Talwalkar, J.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 41, No. 6, 01.12.2016, p. 587-591.

Research output: Contribution to journalComment/debate

Hilscher, M. B. ; Odell, L. J. ; Myhre, L. J. ; Prokop, L. ; Talwalkar, J. / The pharmacotherapy of cirrhosis : concerns and proposed investigations and solutions. In: Journal of Clinical Pharmacy and Therapeutics. 2016 ; Vol. 41, No. 6. pp. 587-591.
@article{f89afb50a18a4aadb16ab00f8d0ff398,
title = "The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions",
abstract = "What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.",
keywords = "drug interaction, liver, pharmacists",
author = "Hilscher, {M. B.} and Odell, {L. J.} and Myhre, {L. J.} and L. Prokop and J. Talwalkar",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/jcpt.12443",
language = "English (US)",
volume = "41",
pages = "587--591",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The pharmacotherapy of cirrhosis

T2 - concerns and proposed investigations and solutions

AU - Hilscher, M. B.

AU - Odell, L. J.

AU - Myhre, L. J.

AU - Prokop, L.

AU - Talwalkar, J.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.

AB - What is known and objective: The presence of cirrhosis has a multifaceted impact on hepatic drug metabolism. An area of concern and uncertainty in the care of patients with cirrhosis is the safe use of both prescription and over-the-counter medications. Comment: Retrospective studies indicate a high incidence of adverse drug reactions (ADRs) among patients with cirrhosis related to use of certain medication classes including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs. Conversely, use of appropriate medications, such as statins, may be decreased in this population due to fear of precipitating hepatotoxicity. What is new and conclusion: Pharmacotherapy in cirrhosis is an area of uncertainty and heterogeneity in clinical practice. Prescribing and dosing guidelines are needed to decrease the risk of serious ADRs in this high-risk patient population.

KW - drug interaction

KW - liver

KW - pharmacists

UR - http://www.scopus.com/inward/record.url?scp=84992192165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992192165&partnerID=8YFLogxK

U2 - 10.1111/jcpt.12443

DO - 10.1111/jcpt.12443

M3 - Comment/debate

C2 - 27576303

AN - SCOPUS:84992192165

VL - 41

SP - 587

EP - 591

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 6

ER -